Rakovina Therapeutics

KT-3000 series

kt-3000 series:  overcoming treatment resistance 

First-generation DDR cancer treatments (PARP-inhibitors) generate billions of dollars in annual revenue and have become important in the treatment BRCA-mutated cancers.

Initially, BRCA-deficient cancers respond well to treatment with PARP-inhibitors, which has greatly improved patient outcomes. However, resistance to PARP-inhibitors develops quickly and has emerged as a significant unmet medical need.


Rakovina Therapeutics’ kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly(ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide meaningful clinical benefit to cancer patients.

Read our publication in the Journal of Clinical Cancer Research demonstrating the potential of kt-3000 series drug candidates against treatment-resistant cancer cell lines. Development of the kt-3000 series is supported, in part, by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.